Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
about
L-asparaginase in the treatment of patients with acute lymphoblastic leukemiaAsparaginase-associated toxicity in children with acute lymphoblastic leukemia.Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia.Asparaginase pharmacology: challenges still to be faced.Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar® in Children with Acute Lymphoblastic Leukemia.Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma.
P2860
Q26738640-494314B4-72DD-4861-AC7C-EE53CD6FE33FQ36762608-884B666A-5A64-4F3D-A9A0-507EFCA9E540Q38577297-7D14BF4E-6125-4EA7-A202-D89BA90990C1Q38755617-836BF5E1-7618-44A4-82B2-76C453B24691Q38933372-1D6B56A3-36B4-4127-8A55-9E7B93D07500Q39135887-0289EDA0-4194-4DF1-9531-704AFE4D76F7Q45072276-1AC3F5E6-50CB-413B-9098-3B14AEC300E8Q48166631-06849330-1DA2-46DF-A16E-BE7F5F58E301Q48353602-7DF65D85-4793-444E-961A-243709E22754Q50143850-39E6FB70-FDA2-44B1-AB10-0123C4F23E60
P2860
Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Pharmacokinetic and pharmacody ...... Oncology Group Study AALL07P4.
@ast
Pharmacokinetic and pharmacody ...... Oncology Group Study AALL07P4.
@en
Pharmacokinetic and pharmacody ...... Oncology Group Study AALL07P4.
@nl
type
label
Pharmacokinetic and pharmacody ...... Oncology Group Study AALL07P4.
@ast
Pharmacokinetic and pharmacody ...... Oncology Group Study AALL07P4.
@en
Pharmacokinetic and pharmacody ...... Oncology Group Study AALL07P4.
@nl
prefLabel
Pharmacokinetic and pharmacody ...... Oncology Group Study AALL07P4.
@ast
Pharmacokinetic and pharmacody ...... Oncology Group Study AALL07P4.
@en
Pharmacokinetic and pharmacody ...... Oncology Group Study AALL07P4.
@nl
P2093
P2860
P356
P1476
Pharmacokinetic and pharmacody ...... Oncology Group Study AALL07P4.
@en
P2093
Andrew J Carroll
Anne L Angiolillo
Ashley R Lane
Brent Wood
Charlotte Wood
Elizabeth A Raetz
Gregory H Reaman
Hao W Zheng
Julie M Gastier-Foster
Meenakshi Devidas
P2860
P304
P356
10.1200/JCO.2014.55.5763
P407
P577
2014-10-27T00:00:00Z